CL2008002933A1 - Uso de una formulacion farmaceutica que comprende una fase hidrofobica, una hidrofilica y al menos un surfactante util para la regulacion de la lipolisis en mamiferos. - Google Patents

Uso de una formulacion farmaceutica que comprende una fase hidrofobica, una hidrofilica y al menos un surfactante util para la regulacion de la lipolisis en mamiferos.

Info

Publication number
CL2008002933A1
CL2008002933A1 CL2008002933A CL2008002933A CL2008002933A1 CL 2008002933 A1 CL2008002933 A1 CL 2008002933A1 CL 2008002933 A CL2008002933 A CL 2008002933A CL 2008002933 A CL2008002933 A CL 2008002933A CL 2008002933 A1 CL2008002933 A1 CL 2008002933A1
Authority
CL
Chile
Prior art keywords
phase
lipolysis
mammals
regulation
pharmaceutical formulation
Prior art date
Application number
CL2008002933A
Other languages
English (en)
Inventor
Garcia Da Silva Reis Neves
Martin Leser
Heribert Johann Watzke
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2008002933A1 publication Critical patent/CL2008002933A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de una formulación farmacéutica, nutracéutica, aditivo alimentario, bebida, producto alimenticio que comprende al menos un surfactante y una fase hidrofílica, útil para regular la lipólisis; composición que comprende al menos un aceite, y enriquecida con al menos un surfactante.
CL2008002933A 2007-10-01 2008-10-01 Uso de una formulacion farmaceutica que comprende una fase hidrofobica, una hidrofilica y al menos un surfactante util para la regulacion de la lipolisis en mamiferos. CL2008002933A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07117649A EP2044930A1 (en) 2007-10-01 2007-10-01 Composition for controlling lipase catalyzed reactions

Publications (1)

Publication Number Publication Date
CL2008002933A1 true CL2008002933A1 (es) 2009-10-16

Family

ID=38926375

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002933A CL2008002933A1 (es) 2007-10-01 2008-10-01 Uso de una formulacion farmaceutica que comprende una fase hidrofobica, una hidrofilica y al menos un surfactante util para la regulacion de la lipolisis en mamiferos.

Country Status (11)

Country Link
US (1) US20110129504A1 (es)
EP (2) EP2044930A1 (es)
JP (1) JP2010540502A (es)
CN (1) CN101868226B (es)
AU (1) AU2008306960A1 (es)
BR (1) BRPI0817938A2 (es)
CL (1) CL2008002933A1 (es)
HK (1) HK1150230A1 (es)
MX (1) MX2010003571A (es)
RU (1) RU2491057C2 (es)
WO (1) WO2009043879A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107630D0 (en) 2011-05-06 2011-06-22 Proxima Concepts Ltd Microemulsions
WO2013015288A1 (ja) * 2011-07-26 2013-01-31 ナガセケムテックス株式会社 リパーゼ活性阻害剤
CN104498545B (zh) * 2014-12-08 2017-11-14 广州嘉德乐生化科技有限公司 一种三聚甘油酯的制备方法
CN104642570A (zh) * 2015-03-11 2015-05-27 重庆第二师范学院 一种玉米胚芽油的改性制备方法
CN104719619B (zh) * 2015-04-21 2017-11-21 重庆威士化工有限公司 一种降低颗粒饲料制粒能耗的饲料添加剂及方法
BR112018072064B8 (pt) * 2016-05-20 2022-08-23 Nestec Sa Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843385B2 (ja) * 1979-07-24 1983-09-27 淳一 岩村 シジミの薬効成分及びその製造法
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5104656A (en) * 1989-06-16 1992-04-14 Seth Pyare L Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
JP3098561B2 (ja) * 1991-03-28 2000-10-16 花王株式会社 血清トリグリセリド濃度低下剤
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP4761093B2 (ja) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
JP4612930B2 (ja) * 2000-04-19 2011-01-12 花王株式会社 レムナント様リポタンパク低下剤
US20020103139A1 (en) * 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
JP2002322052A (ja) * 2001-04-26 2002-11-08 Kao Corp 小腸上皮中の脂質代謝改善剤
DE10247399A1 (de) * 2002-10-08 2004-04-29 Schering Ag Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen
CN1997282A (zh) * 2004-03-11 2007-07-11 马萨诸塞州立大学 脂质系统的生物聚合物包封和稳定性及其应用方法

Also Published As

Publication number Publication date
AU2008306960A1 (en) 2009-04-09
WO2009043879A1 (en) 2009-04-09
JP2010540502A (ja) 2010-12-24
RU2491057C2 (ru) 2013-08-27
BRPI0817938A2 (pt) 2015-05-05
HK1150230A1 (en) 2011-11-11
MX2010003571A (es) 2010-04-21
RU2010117234A (ru) 2011-11-10
CN101868226B (zh) 2012-07-04
EP2044930A1 (en) 2009-04-08
EP2205216A1 (en) 2010-07-14
US20110129504A1 (en) 2011-06-02
CN101868226A (zh) 2010-10-20

Similar Documents

Publication Publication Date Title
CL2008002933A1 (es) Uso de una formulacion farmaceutica que comprende una fase hidrofobica, una hidrofilica y al menos un surfactante util para la regulacion de la lipolisis en mamiferos.
BRPI1007782A2 (pt) Composições concentradas, cremosas para sólidas e secas, de uma emulsão de óleo em água, método para a produção destas e uso destas para a produção de alimentos melhorados em termos sensoriais e fisiologia da nutrição.
EP1972330A3 (en) Cosmetic or pharmaceutical compositions comprising modified polysiloxanes with at least one carbamate group
CL2011003078A1 (es) Uso de una composicion nutricional para mantener, sostener y/o mejorar el desempeno cognitivo en un nino de 3 a 6 anos, que comprende al menos una fuente de proteina, una fuente de carbohidratos, una fuente de lipido, un microorganismo probiotico, y prebioticos, en donde la fuente de lipido comprende acido docosahexanoico (dha).
WO2008021531A3 (en) Stabilized emulsions, methods of preparation, and related reduced fat foods
EP2123257A3 (en) Stable high Vitamin C content polyol-in-oil emulsified system and its preparation
AR064614A1 (es) Producto combinado par controlar parasitos en animales
AU2008313418A8 (en) Composition for regulating lipid metabolism
GT201300313A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
BRPI0610786B8 (pt) uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia
WO2008113483A3 (de) Stabilisierung von vitamin b12
BRPI1010369B8 (pt) composição cosmética em forma de nanoemulsão óleo-em-água e uso de uma composição
BRPI0919901A2 (pt) Composição nutricional líquida aquosa estável em prateleira, método para a produção de uma composição e uso de uma composição.
WO2011152730A3 (en) Stable high lipid liquid formula
ES2528412T3 (es) Espumas de alimentos y bebidas
WO2012001172A3 (en) Cosmetic composition comprising at least one organopolysiloxane elastomer and at least one tackifying resin
BR112013033210A2 (pt) produto de fibra para embalagem, método para a produção de um produto de fibra, aparelho para a produção de um produto de fibra, embalagem de alimento e uso de um material de filtro em um produto de fibra
AU2013269583A8 (en) Oil/water-emulsion-type topical compositions containing a retinoid
CL2012003715A1 (es) Composicion fungicida sinergica de amplio espectro adecuada para su uso en la conservacion de un producto de madera encolada que comprende triadimefon y ciproconazol; método para la conservación de un producto de madera encolado.
AR087059A1 (es) Formulacion que contiene leche como base
WO2007109071A3 (en) Hydroxylated polymethoxyflavone compositions
WO2010000645A3 (de) Haarkonditionierende mittel mit imidazolinen
NI201000212A (es) Dronedarona para la prevención de la cardioversión.
BR112012033739A8 (pt) Isomaltulose para uso no aumento do desempenho mental
WO2011029516A3 (de) Kosmetische zusammensetzung mit antimikrobieller wirkung